Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome.
about
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamideIdentification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysisThe role of androgens in experimental rodent mammary carcinogenesisTargeting the androgen receptor in prostate and breast cancer: several new agents in developmentA phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumorsTreatment options in androgen-independent prostate cancer.Hormone-refractory prostate cancer? Anti-androgen withdrawal and intermittent hormone therapy.Androgen receptor signalling in the prostate.Hormonal therapy for prostate cancer: past, present and future.Hormonal treatment for prostate cancer.Androgen receptor antagonists in castration-resistant prostate cancer.Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.Pharmacotherapy for biochemical recurrences after therapy for localised prostate cancer.The androgen receptor: structure, mutations, and antiandrogens.Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate CancerSmall-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic TaggingAntiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)Hormetic effects of hormones, antihormones, and antidepressants on cancer cell growth in culture: in vivo correlates.A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.Castrate-resistant prostate cancer: therapeutic strategies.Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.The type of patients who would benefit from anti-androgen withdrawal therapy: could it be performed safely for aggressive prostate cancer?Novel agents in the management of castration resistant prostate cancer.Nonmetastatic castration-resistant prostate cancer.Switching and withdrawing hormonal agents for castration-resistant prostate cancer.Is there an anti-androgen withdrawal syndrome for enzalutamide?Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case reportThe palliative therapy of advanced prostate cancer, with particular reference to the results of recent European clinical trials.Combined androgen blockade in the treatment of advanced prostate cancer--an overview. The Scandinavian Prostatic Cancer Group.Expression, structure, and function of androgen receptor in advanced prostatic carcinoma.Delayed antiandrogen withdrawal syndrome after discontinuation of bicalutamideThe transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor functionTreatment algorithm in hormone-resistant prostate cancer: Practical guidelines.Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens.Androgen Deprivation for Prostatic Carcinoma: A Rationale for Choosing ComponentsIs there an antiandrogen withdrawal syndrome with enzalutamide?
P2860
Q21195191-F9570171-3755-4836-AE18-43AFAA798474Q24301596-40F878A9-DD77-4E5A-BE17-A3786A2689CDQ26864598-9D1BA349-965B-4FF6-B3FE-D15E2FE63E5BQ27009424-8D67D773-D75C-4CC8-9D18-24C1D39D7B6AQ28304273-B8847360-E6DC-4D81-9941-1E31BC685C1DQ33539954-A2084D40-2F32-47A7-9840-E8A7FE195408Q33748701-907E49E4-7112-4B83-9C41-5EB4CD2428FFQ34105526-CCC9A38E-1761-4B9B-93F7-74383F857A79Q34138275-4D2D6075-BE55-4D6D-AAFF-FC5A234D5F4CQ34167174-74FB905B-793C-47AA-9FD6-BD3CF271C2BFQ34323656-B6132586-38F2-4E57-9D1E-212AAA36670BQ34596863-394DFAB4-9489-442B-BEC9-621B67170D0FQ34660732-EFB74213-FB1A-4254-A567-3CD0973C46F7Q35193278-CB0E6CB4-98CA-4C46-B397-69AE705583D9Q35210730-11AC4537-4EAC-49DB-AA22-9679D40C10E7Q35666096-B0ADB3FD-8AB9-4CCD-A064-16895F94CCBCQ35987124-B8C02007-56E7-47AD-9C1D-D974504F9EC7Q36372263-CD711BD0-4462-4ADF-9956-719D023C8F03Q37318328-953BC8B5-F3D9-46F0-B7AF-6BB836567FC5Q37716009-911404EA-4A8E-4896-B6A0-428872C5AA60Q37950948-751A9320-5B5C-448D-B5AB-3B0531D6F909Q38116790-5547BB17-E0B6-48AB-B83E-D906FCC14246Q38209656-4D6E6B80-46B3-49D5-9AFD-8880BDBB98D5Q38306052-940D59A8-FF7E-4090-A908-43C047E2C1CAQ38309205-EB11FA84-404C-477E-9203-935DF3529D54Q39217798-44AB341A-D4B9-434B-BF57-F62571462FCBQ39445208-F7AA2497-22ED-4C26-BABC-65D2FDA0B703Q41183254-D5CD9906-DB6B-4A74-AD0F-44F388E8EAD1Q41409558-4A8EBABA-532A-487E-A640-FC3EB066CA87Q41556362-3B83AB27-D254-4B51-9C50-24863A0CE59EQ41736561-CA0D9712-81CB-492E-849A-DCD2570C4CE0Q42096206-9DF64453-6489-4590-8BCF-6347F4E9EF3FQ42153519-DFC32162-B9A4-4143-BA89-55A780774D70Q43077983-A02A2EF5-940A-4156-A261-6230802E4822Q46004084-DAA3B0E6-F7C4-4581-A501-D734CC0E944FQ46694974-DF76D33A-BAD3-4C04-BF09-387A7BD8B282Q52677958-58722AF8-0A01-4398-B11C-DCB84EE4A423Q56672866-20386601-0016-4E44-A8B9-3E8617EBFBAEQ58813328-04F9DDF2-9B71-47AE-98DB-86136071C6A1
P2860
Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Prostate-specific antigen decl ...... iandrogen withdrawal syndrome.
@en
Prostate-specific antigen decl ...... iandrogen withdrawal syndrome.
@nl
type
label
Prostate-specific antigen decl ...... iandrogen withdrawal syndrome.
@en
Prostate-specific antigen decl ...... iandrogen withdrawal syndrome.
@nl
prefLabel
Prostate-specific antigen decl ...... iandrogen withdrawal syndrome.
@en
Prostate-specific antigen decl ...... iandrogen withdrawal syndrome.
@nl
P1433
P1476
Prostate-specific antigen decl ...... iandrogen withdrawal syndrome.
@en
P2093
P R Carroll
P304
P356
10.1016/0090-4295(94)90092-2
P407
P577
1994-03-01T00:00:00Z